The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 14, 2018
Filed:
Jun. 13, 2014
Applicant:
Servicio Andaluz DE Salud, Sevilla, ES;
Inventors:
José Antonio Pérez Simón, Sevilla, ES;
María Victoria Barbado González, Sevilla, ES;
Assignee:
SERVICIO ANDALUZ DE SALUD, Sevilla, ES;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A01N 37/36 (2006.01); A61K 31/60 (2006.01); A61K 31/5383 (2006.01); A61K 31/198 (2006.01); A61K 31/395 (2006.01); A61K 31/454 (2006.01); A61K 31/573 (2006.01); A61K 31/69 (2006.01); A61K 31/704 (2006.01); A61K 38/07 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5383 (2013.01); A61K 31/198 (2013.01); A61K 31/395 (2013.01); A61K 31/454 (2013.01); A61K 31/573 (2013.01); A61K 31/69 (2013.01); A61K 31/704 (2013.01); A61K 38/07 (2013.01); A61K 45/06 (2013.01);
Abstract
The present invention relates to the use of compounds of a cannabinoid nature for inhibiting viability with increasing doses of myeloma cell lines. Furthermore, said compounds have been shown not to affect CD34+ cells (normal hematopoietic progenitors) in terms of viability and proliferation. For this reason, the invention paves the way for the use of compounds of a cannabinoid nature as a promising therapy against multiple myeloma and related diseases.